Abstract:Key PointsScientific advancement in neuroscience has not been effectively translated into therapies for neurological diseases. In general, 'toxin reducing' approaches (for example, lowering amyloid-β (Aβ)) thus far have not resulted in halting or delaying disease progression. A paradigm shift in the discovery of disease-modifying therapies for neurological diseases is urgently needed.For neurodegenerative diseases, targeting the pathophysiology rather than the pathogenesis may be more effective to achieve therapeutic intervention. The toxin reducing approach may work if treatment starts very early on in the disease process.Synapse degeneration is a major pathophysiological feature that correlates with disease progression in multiple neurodegenerative diseases. Neuronal loss is irreversible, whereas synapses can be repaired and regenerated.Three aspects of synaptic physiology can be targeted: synaptic transmission, synaptic plasticity and synaptic growth. For disease-modifying therapy, synaptic plasticity and, more importantly, synaptic growth should be targeted.Brain-derived neurotrophic factor (BDNF) is an exemplar of synaptic repair therapy, as it regulates all three aspects of synaptic physiology. It protects and repairs existing synapses and stimulates new synapse formation, even in the presence of various toxins.In humans, the BDNF Val66Met polymorphism in conjunction with high Aβ deposits confers faster decline in Alzheimer's disease endophenotypes such as episodic memory and hippocampal volume, and therefore could be considered as a patient stratification strategy for clinical trials with enhanced sensitivity and robustness.Success of a 'synaptic repair' therapy depends on whether synaptic dysfunction and synaptic repair and/or regeneration can be measured in the clinic. Efforts should be made to develop sensitive and reliable methodologies to measure synaptic function in humans in vivo.Opportunities and challenges in developing BDNF–TRKB pathway-based therapies, including delivery, are discussed.A combination of synaptic therapy and a more reliable and sensitive method (or methods) to measure synaptic changes may pave the way for developing disease-modifying medicines for debilitating neurological diseases. This Review highlights recent discoveries, discusses emerging concepts and proposes synapse-based therapies for treating neurodegenerative diseases.

Targeting the Synapse in Alzheimer’s Disease

The synapse as a treatment avenue for Alzheimer’s Disease

Targeting synapse function and loss for treatment of neurodegenerative diseases

The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

Targeting Synaptic Pathology in Alzheimer’s Disease

Targeting epigenetic mechanisms in amyloid-β-mediated Alzheimer's pathophysiology: unveiling therapeutic potential

Treating Alzheimer's Disease: Focusing on Neurodegenerative Consequences

Synaptic Function As a Preclinical and Experimental Medicine Readout for Disease-Modifying Therapy in Alzheimer's Disease

BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases

Pathological mechanisms and therapeutic strategies for Alzheimer’s disease

Studying synaptic plasticity in the human brain and opportunities for drug discovery

MicroRNAs and synapse turnover in Alzheimer's disease

Targeting Microglia-Synapse Interactions in Alzheimer's Disease

The neurotransmitter puzzle of Alzheimer's: Dissecting mechanisms and exploring therapeutic horizons

Mechanistic insights and emerging therapeutic stratagems for Alzheimer's disease

Altered synaptic plasticity at hippocampal CA1-CA3 synapses in Alzheimer's disease: integration of amyloid precursor protein intracellular domain and amyloid beta effects into computational models

Alzheimer's therapeutic development: shifting neurodegeneration to neuroregeneration

Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer's Disease and Identifying Promising Drug Targets

Gene expression parallels synaptic excitability and plasticity changes in Alzheimer’s disease

Impaired brain plasticity as a potential therapeutic target for treatment and prevention of dementia

Neurotransmitters in Prevention and Treatment of Alzheimer's Disease